Algeta Signs Exclusive License Agreement with Lumiphore, Inc.

News   May 02, 2013

 
Algeta Signs Exclusive License Agreement with Lumiphore, Inc.
 
 
 

RELATED ARTICLES

Pathway in Neurons may Contribute to Neurodegenerative Disease

News

Pathway has received attention as potential drug target.

READ MORE

APEIRON Strengthens Management Board

News

Industry expert Peter Llewellyn-Davies joins as New Chief Financial Officer.

READ MORE

Some 30,000 Biomedical Publications Report on Misidentified Cells

News

Researchers from Radboud University have found more than 30,000 publications are reporting on the wrong cells.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE